fda and semaglutide ban on compounding news alerts health care providers, compounders patients of dosing errors associated with compounded injectable products The FDA's Decision to – FDA approves obesity drug that – Ozempic picks up FDA indication

Although GLP-1RAs can attenuate inflammatory tone [105], sustained reductions in nutrient inflow associated with pharmacological weight loss may influence NAD turnover kinetics in metabolically stressed tissues

doi: 10.1046/j.1365-2826.1998.00187.x 57 KanayamaGHudsonJIPopeHGJr

The most common side effect of GLP-1RAs is nausea and vomiting, which are hypothesized to result from inhibition of gastric emptying

Acknowledgements This work was supported by National Research Foundation grants [2021R1A5A2021614, 2021R1A2C1005513, and 2022M3A9G8095334] funded by the Ministry of Science and ICT of Korea

The bottom line Similar to the treatments for other chronic conditions, medications to manage obesity are designed to be taken long-term, even after you reach your weight-loss goal